13 November 2026
Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy
Primary endpoint achieved: PVX108 therapy increased the maximum tolerated dose of peanut compared to placebo following a convenient, once- monthly treatment course over 12 months, while demonstrating a highly favourable safety and tolerability profile Multiple secondary and exploratory objectives were also met, including a significant reduction in emotional impact of allergy reported by children following […]
